Tipranavir cost effective in treatment-experienced HIV

July 2006
PharmacoEconomics & Outcomes News;7/15/2006, Issue 507, p8
Discusses research being done on the cost effectiveness of tipranavir for treatment-experienced patients with HIV infections. Reference to a study by K. N. Simpson et al, published in the May to June 2006 issue of "Value in Health"; Range of the incremental cost-effectiveness ratio for ritonavir-boosted tipranavir; Safety and efficacy of ritonavir-boosted tipranavir.


Related Articles

  • Addition of enfuvirtide: is it worth it in advanced HIV?  // PharmacoEconomics & Outcomes News;7/2/2005, Issue 481, p10 

    Presents the results of a study on the effectiveness of enfuvirtide treatment in patients with HIV infection. Projected quality-adjusted life expectancy (QALY) for patients who received optimized therapy; Cost effectiveness of enfuvirtide plus optimized therapy per QALY.

  • A Microsimulation of the Cost-effectiveness of Maraviroc for Antiretroviral Treatment-Experienced HIV-Infected Individuals. Kühne, Felicitas C.; Chancellor, Jeremy; Mollon, Patrick; Myers, Daniela E.; Louie, Michael; Powderly, William G. // HIV Clinical Trials;Mar/Apr2010, Vol. 11 Issue 2, p80 

    Purpose: Maraviroc (MVC) is the first approved CCR5 antagonist. The aim of this study was to explore the cost-effectiveness of MVC in treatment-experienced or treatment-resistant HIV-infected adults.Methods: The validated HIV microsimulation model ARAMIS was used to predict clinical and economic...

  • treatment-naïve:. Huber, Jeffrey T.; Gillaspy, Mary L. // Encyclopedic Dictionary of AIDS-Related Terminology;2000, p216 

    A definition of the term "treatment-naïve" is presented. It refers to patients who have no history of having been treated for a specific condition with a particular drug. HIV-positive persons who have not been subjected to monotherapy have the best chance of driving their viral load to...

  • HIV treatments -- the state of play. Maynard, Tony // HIV Australia;Jun-Aug2004, Vol. 3 Issue 4, p20 

    Traces the progress of HIV medication in Australia. Conditions of people living with HIV/AIDS diseases; Situations that call for the treatment of the disease; Classes of drugs formulated for the disease; Factors that contributed to the success of HIV medication.

  • "Significant cost savings" accrued with discontinuation of HAART.  // PharmacoEconomics & Outcomes News;8/27/2005, Issue 485, p9 

    Discusses research being done on cost saving and clinical outcome associated with the discontinuation of therapy in HIV patients. Reference to a study by P. Keiser and colleagues, presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment in July 2005;...

  • Cross Regulation of Sirtuin 1, AMPK, and PPARγ in Conjugated Linoleic Acid Treated Adipocytes. Shan Jiang; Wei Wang; Miner, Jess; Fromm, Michael // PLoS ONE;Nov2012, Vol. 7 Issue 11, Special section p1 

    Trans-10, cis-12 conjugated linoleic acid (t10c12 CLA) reduces triglyceride (TG) levels in adipocytes through multiple pathways, with AMP-activated protein kinase (AMPK) generally facilitating, and peroxisome proliferator-activated receptor γ (PPARγ) generally opposing these reductions....

  • Cost-Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV-Infected Persons with a CD4+ Cell Count ⩽100 Cells/μL Who Start HIV Therapy in Resource-Limited Settings. Meya, David B.; Manabe, Yukari C.; Castelnuovo, Barbara; Cook, Bethany A.; Elbireer, Ali M.; Kambugu, Andrew; Kamya, Moses R.; Bohjanen, Paul R.; Boulware, David R. // Clinical Infectious Diseases;8/15/2010, Vol. 51 Issue 4, p448 

    Background. Cryptococcal meningitis (CM) remains a common AIDS-defining illness in Africa and Asia. Subclinical cryptococcal antigenemia is frequently unmasked with antiretroviral therapy (ART).We sought to define the cost-effectiveness of serum cryptococcal antigen (CRAG) screening to identify...

  • The Cost-Effectiveness of Monitoring Strategies for Antiretroviral Therapy of HIV Infected Patients in Resource-Limited Settings: Software Tool. Estill, Janne; Salazar-Vizcaya, Luisa; Blaser, Nello; Egger, Matthias; Keiser, Olivia // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    Background: The cost-effectiveness of routine viral load (VL) monitoring of HIV-infected patients on antiretroviral therapy (ART) depends on various factors that differ between settings and across time. Low-cost point-of-care (POC) tests for VL are in development and may make routine VL...

  • The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy. Ross, Eric L.; Weinstein, Milton C.; Schackman, Bruce R.; Sax, Paul E.; Paltiel, A. David; Walensky, Rochelle P.; Freedberg, Kenneth A.; Losina, Elena // Clinical Infectious Diseases;Apr2015, Vol. 60 Issue 7, p1102 

    Background. Long-acting antiretroviral therapy (LA-ART) is currently under development and could improve outcomes for human immunodeficiency virus (HIV)-infected individuals with poor daily ART adherence. Methods. We used a computer simulation model to evaluate the cost-effectiveness of 3 LA-ART...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics